Atomi Financial Group Inc. Invests $162,000 in Dr. Reddy’s Laboratories Limited (NYSE:RDY)

Atomi Financial Group Inc. purchased a new position in Dr. Reddy’s Laboratories Limited (NYSE:RDY) during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund purchased 10,271 shares of the company’s stock, valued at approximately $162,000.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the business. Farther Finance Advisors LLC increased its holdings in Dr. Reddy’s Laboratories by 43.2% during the 3rd quarter. Farther Finance Advisors LLC now owns 454 shares of the company’s stock worth $36,000 after purchasing an additional 137 shares during the last quarter. Venturi Wealth Management LLC acquired a new stake in shares of Dr. Reddy’s Laboratories during the third quarter worth approximately $60,000. Van ECK Associates Corp increased its stake in shares of Dr. Reddy’s Laboratories by 64.3% in the third quarter. Van ECK Associates Corp now owns 823 shares of the company’s stock worth $64,000 after buying an additional 322 shares during the last quarter. GAMMA Investing LLC raised its holdings in Dr. Reddy’s Laboratories by 369.9% in the fourth quarter. GAMMA Investing LLC now owns 6,799 shares of the company’s stock valued at $107,000 after acquiring an additional 5,352 shares in the last quarter. Finally, Abacus Wealth Partners LLC bought a new position in Dr. Reddy’s Laboratories during the 4th quarter valued at $160,000. Hedge funds and other institutional investors own 3.85% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms have recently weighed in on RDY. Barclays dropped their target price on shares of Dr. Reddy’s Laboratories from $17.40 to $17.00 and set an “overweight” rating for the company in a research report on Wednesday, November 6th. Nomura downgraded Dr. Reddy’s Laboratories from a “buy” rating to a “neutral” rating in a research note on Thursday, December 19th. Finally, StockNews.com cut Dr. Reddy’s Laboratories from a “buy” rating to a “hold” rating in a research note on Friday, December 6th.

Dr. Reddy’s Laboratories Stock Performance

Dr. Reddy’s Laboratories stock opened at $13.66 on Tuesday. The company has a debt-to-equity ratio of 0.02, a current ratio of 1.92 and a quick ratio of 1.36. Dr. Reddy’s Laboratories Limited has a 12 month low of $13.59 and a 12 month high of $16.89. The company has a fifty day moving average price of $14.86 and a two-hundred day moving average price of $15.50. The company has a market cap of $11.40 billion, a PE ratio of 21.81 and a beta of 0.51.

Dr. Reddy’s Laboratories (NYSE:RDY) last announced its quarterly earnings data on Thursday, January 23rd. The company reported $0.20 earnings per share for the quarter, beating analysts’ consensus estimates of $0.19 by $0.01. Dr. Reddy’s Laboratories had a net margin of 17.81% and a return on equity of 18.53%. Research analysts expect that Dr. Reddy’s Laboratories Limited will post 0.81 earnings per share for the current year.

About Dr. Reddy’s Laboratories

Dr. Reddy’s Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company’s Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business.